122 related articles for article (PubMed ID: 35315165)
1. A global view of adherence to colonoscopy follow-up in cascade screening of colorectal cancer.
Yang Y; Huang J; Wu W; Luu HN; Moy FM; Tan S; Fu J; Ying T; Withers M; Hung DT; Mao D; Chen S; Wong MCS; Xu W
Eur J Cancer Care (Engl); 2022 Sep; 31(5):e13577. PubMed ID: 35315165
[TBL] [Abstract][Full Text] [Related]
2. Adherence to colonoscopy in cascade screening of colorectal cancer: A systematic review and meta-analysis.
Wu W; Huang J; Yang Y; Gu K; Luu HN; Tan S; Yang C; Fu J; Bao P; Ying T; Withers M; Mao D; Chen S; Gong Y; Wong MCS; Xu W
J Gastroenterol Hepatol; 2022 Apr; 37(4):620-631. PubMed ID: 34907588
[TBL] [Abstract][Full Text] [Related]
3. Motives for non-adherence to colonoscopy advice after a positive colorectal cancer screening test result: a qualitative study.
Bertels L; Lucassen P; van Asselt K; Dekker E; van Weert H; Knottnerus B
Scand J Prim Health Care; 2020 Dec; 38(4):487-498. PubMed ID: 33185121
[TBL] [Abstract][Full Text] [Related]
4. Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation.
Daniels K; McKee M
J R Army Med Corps; 1995 Oct; 141(3):142-50. PubMed ID: 8568748
[TBL] [Abstract][Full Text] [Related]
5. Options for screening for colorectal cancer.
Atkin W
Scand J Gastroenterol Suppl; 2003; (237):13-6. PubMed ID: 12797674
[TBL] [Abstract][Full Text] [Related]
6. Barriers to completing colonoscopy after a positive fecal occult blood test.
Azulay R; Valinsky L; Hershkowitz F; Elran E; Lederman N; Kariv R; Braunstein B; Heymann A
Isr J Health Policy Res; 2021 Feb; 10(1):11. PubMed ID: 33573698
[TBL] [Abstract][Full Text] [Related]
7. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
Peng SM; Hsu WF; Wang YW; Lin LJ; Yen AM; Chen LS; Lee YC; Wu MS; Chen TH; Chiu HM
Gut; 2021 Jul; 70(7):1318-1324. PubMed ID: 32989019
[TBL] [Abstract][Full Text] [Related]
8. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Lin JS; Perdue LA; Henrikson NB; Bean SI; Blasi PR
JAMA; 2021 May; 325(19):1978-1998. PubMed ID: 34003220
[TBL] [Abstract][Full Text] [Related]
9. Evidence for colorectal cancer screening.
Bretthauer M
Best Pract Res Clin Gastroenterol; 2010 Aug; 24(4):417-25. PubMed ID: 20833346
[TBL] [Abstract][Full Text] [Related]
10. Repeated Automated Mobile Text Messaging Reminders for Follow-Up of Positive Fecal Occult Blood Tests: Randomized Controlled Trial.
Azulay R; Valinsky L; Hershkowitz F; Magnezi R
JMIR Mhealth Uhealth; 2019 Feb; 7(2):e11114. PubMed ID: 30720439
[TBL] [Abstract][Full Text] [Related]
11. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
12. Screening for colorectal cancer using the faecal occult blood test, Hemoccult.
Hewitson P; Glasziou P; Irwig L; Towler B; Watson E
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD001216. PubMed ID: 17253456
[TBL] [Abstract][Full Text] [Related]
13. Changes in colorectal cancer screening use after introduction of alternative screening offer in Germany: Prospective cohort study.
Guo F; Chen C; Schöttker B; Holleczek B; Hoffmeister M; Brenner H
Int J Cancer; 2020 May; 146(9):2423-2432. PubMed ID: 31291471
[TBL] [Abstract][Full Text] [Related]
14. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.
Hardcastle JD; Chamberlain JO; Robinson MH; Moss SM; Amar SS; Balfour TW; James PD; Mangham CM
Lancet; 1996 Nov; 348(9040):1472-7. PubMed ID: 8942775
[TBL] [Abstract][Full Text] [Related]
15. Adherence to national guidelines for colorectal cancer screening in Israel: Comprehensive multi-year assessment based on electronic medical records.
Paltiel O; Keidar Tirosh A; Paz Stostky O; Calderon-Margalit R; Cohen AD; Elran E; Valinsky L; Matz E; Krieger M; Yehuda AB; Jaffe DH; Manor O
J Med Screen; 2021 Mar; 28(1):25-33. PubMed ID: 32356670
[TBL] [Abstract][Full Text] [Related]
16. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
[TBL] [Abstract][Full Text] [Related]
17. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection.
Hundt S; Haug U; Brenner H
Ann Intern Med; 2009 Feb; 150(3):162-9. PubMed ID: 19189905
[TBL] [Abstract][Full Text] [Related]
18. Systematic review with meta-analysis: faecal occult blood tests show lower colorectal cancer detection rates in the proximal colon in colonoscopy-verified diagnostic studies.
Hirai HW; Tsoi KK; Chan JY; Wong SH; Ching JY; Wong MC; Wu JC; Chan FK; Sung JJ; Ng SC
Aliment Pharmacol Ther; 2016 Apr; 43(7):755-64. PubMed ID: 26858128
[TBL] [Abstract][Full Text] [Related]
19. The role of faecal calprotectin in the identification of colorectal neoplasia in patients attending for screening colonoscopy.
Ross FA; Park JH; Mansouri D; Little C; Di Rollo DG; Combet E; Van Wyk H; Horgan PG; McMillan DC; Roxburgh CSD
Colorectal Dis; 2022 Feb; 24(2):188-196. PubMed ID: 34614299
[TBL] [Abstract][Full Text] [Related]
20. Impact of colorectal cancer screening participation in remote northern Canada: A retrospective cohort study.
Smith HA; Scarffe AD; Brunet N; Champion C; Kandola K; Tessier A; Boushey R; Kuziemsky C
World J Gastroenterol; 2020 Dec; 26(48):7652-7663. PubMed ID: 33505142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
